tradmap

BBOT Earnings BridgeBio Oncology Therapeutics, Inc.

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated

Annual results

Diluted EPS (annual)
-$5756 -$2878 $0 2024 2025
EPS
Net income (annual)
-$134M -$67M $0 2023 2024 2025
Net income
Return on equity (annual)
-33% 4% 42% 0% 2023 2024 2025
ROE

Quarterly results

Diluted EPS (quarterly)
-$4923 -$2461 $0 Q3 '24 Q1 '25 Q2 '25 Q3 '25 Q1 '26 Q2 '26
EPS
Net income (quarterly)
-$56M -$28M $1M $0 Q1 '24 Q2 '24 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26
Net income
Return on equity (quarterly)
-17% -1% 15% 0% Q1 '24 Q2 '24 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26
ROE

Reported EPS history

1–8 of 8
Q2 20262026-06-30-1230.892026-08-1110-Q
Q1 20262026-03-31-526.112026-05-1210-Q
FY 20252025-12-31-4.302026-03-0510-K
Q3 20252025-09-30-6.492025-11-1210-Q
Q2 20262025-06-30-1168.262026-08-1110-Q
Q1 20262025-03-31-54.232026-05-1210-Q
FY 20252024-12-31-5756.412026-03-0510-K
Q3 20252024-09-30-4922.722025-11-1210-Q

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.